# CGEM catalysts: Cullinan Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cgem/catalysts

> Cullinan Therapeutics, Inc. (CGEM) has 2 upcoming catalysts. The next is the CLN-978 trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CGEM?

Cullinan Therapeutics, Inc. (CGEM) has 2 upcoming catalysts. The next is the CLN-978 trial start, Q1 2027. SEC Form 8-K: "The Company plans to initiate a Phase 1/2a clinical trial in the first quarter of 2027 in patients with autoimmune cytopenias, including immune thrombocytopenia and autoimmune hemolytic anemia, autoantibody-mediated diseases with high unmet need." [Calendar and source filings](https://sec-api.dev/companies/cgem/catalysts)

Source: SEC Form 8-K, accession 0001193125-26-264916, https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/cgem-20260610.htm (retrieved 2026-11-12). Last confirmed 2026-06-10. Cite: https://sec-api.dev/companies/cgem/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Cullinan Therapeutics, Inc. |
| Ticker | CGEM (Nasdaq) |
| SEC CIK | 1789972 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/cgem |

## Cash runway

Cash $311.5M as of 2026-09-30; quarterly burn $43.1M; about 21.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-454417).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [Zipalertinib trial start](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | completed | "In November 2022, in collaboration with our partners at Taiho, we initiated the ongoing, pivotal Phase 2b portion of the REZILIENT1 clinical trial of zipalertinib 100 mg twice daily in adult NSCLC patients with EGFRex20ins mutations who progressed after prior systemic therapy." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| Aug 2023 | [Zipalertinib trial start](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | completed | "In August 2023, our collaboration partners at Taiho initiated the ongoing global Phase 3 clinical trial testing zipalertinib plus standard-of-care chemotherapy versus standard-of-care chemotherapy alone in frontline adult NSCLC patients with EGFRex20ins mutations (REZILENT3)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| Dec 2023 | [CLN-617 trial start](https://sec-api.dev/pdufa/cln-617) | CGEM | advanced solid tumors | completed | "In December 2023, we dosed the first patient in the ongoing Phase 1 clinical trial of CLN-617 in patients with advanced solid tumors." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| Dec 2023 | [CLN-049 trial start](https://sec-api.dev/pdufa/cln-049) | CGEM | AML and measurable residual disease | completed | "In December 2023, we initiated the ongoing Phase 1 clinical trial designed to evaluate the safety and preliminary efficacy of CLN-049 in patients with AML and measurable residual disease following induction therapy." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000119312526099362/cgem-20251231.htm)) |
| Sep 2024 | [CLN-619 trial start](https://sec-api.dev/pdufa/cln-619) | CGEM | relapsed/refractory multiple myeloma | completed | "In September 2024, we dosed the first patient in the ongoing Phase 1 clinical trial to evaluate CLN-619 in patients with relapsed/refractory multiple myeloma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| Dec 2024 | [CLN-978 trial start](https://sec-api.dev/pdufa/cln-978) | CGEM | moderate to severe SLE | completed | "In December 2024, we initiated the ongoing Phase 1 clinical trial in patients with moderate to severe SLE." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| February 27, 2025 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/cgem-ex99_1.htm)) |
| Q2 2025 | [CLN-619 interim data readout](https://sec-api.dev/pdufa/cln-619) | CGEM |  | scheduled | "Initial data from the disease specific expansion cohorts for endometrial and cervical cancers are anticipated in the second quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| Q2 2025 | [CLN-978 trial start](https://sec-api.dev/pdufa/cln-978) | CGEM | rheumatoid arthritis | scheduled | "In the second quarter of 2025, we plan to initiate a company-sponsored Phase 1 clinical trial to evaluate CLN-978 in patients with rheumatoid arthritis ("RA"), designed and executed in collaboration with the Friedrich-Alexander University of Erlangen-Nuremberg and Università Cattolica del Sacro Cuore, Rome." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| May 8, 2025 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/cgem-ex99_1.htm)) |
| August 7, 2025 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000095017025104547/cgem-ex99_1.htm)) |
| late 2025 | [RYBREVANT (amivantamab) NDA/BLA submission](https://sec-api.dev/pdufa/amivantamab) | CGEM |  | scheduled | "Pending discussions with the U.S. Food and Drug Administration, Taiho plans to submit an NDA in relapsed EGFR ex20ins NSCLC by the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000095017025104547/cgem-ex99_1.htm)) |
| Q4 2025 | [CLN-978 interim data readout](https://sec-api.dev/pdufa/cln-978) | CGEM | moderate to severe SLE | scheduled | "Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/cgem-ex99_1.htm)) |
| Oct 2025 | [Zipalertinib interim data readout](https://sec-api.dev/pdufa/zipalertinib) | CGEM | active brain metastases | scheduled | "Taiho also plans to share initial data from the REZILIENT2 cohort exploring zipalertinib in patients with active brain metastases at the European Society for Medical Oncology Congress 2025 in October 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1789972/000095017025104551/cgem-20250630.htm)) |
| November 6, 2025 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/cgem-ex99_1.htm)) |
| Q1 2026 | [Zipalertinib NDA/BLA submission](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | scheduled | "Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-ex99_1.htm)) |
| January 8, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "The Company expects to report its fourth quarter and full-year 2025 financial results in late February 2026 which will contain additional information required for a more complete understanding of the Company's financial position and results of operations as of and for the year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-ex99_1.htm)) |
| March 10, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/cgem-ex99_1.htm)) |
| May 7, 2026 | [Zipalertinib NDA/BLA acceptance](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | completed | ""Further, with our partner Taiho, we announced FDA acceptance of our first NDA submission, representing a significant milestone for Cullinan Therapeutics and bringing zipalertinib meaningfully closer to being available for patients, with a PDUFA date of February 27, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm)) |
| May 7, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm)) |
| Jun 2026 | [CLN-978 interim data readout](https://sec-api.dev/pdufa/cln-978) | CGEM | active, difficult-to-treat RA | scheduled | "We are well-positioned to further concentrate resources on CLN-978, a CD19xCD3 bispecific T cell engager, and we plan to share initial clinical data in autoimmune diseases in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/cgem-ex99_1.htm)) |
| June 6, 2026 | [Cullinan Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | scheduled | "The initial data will be presented in a poster session at the EULAR 2026 Congress on June 6, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm)) |
| Q3 2026 | [CLN-978 interim data readout](https://sec-api.dev/pdufa/cln-978) | CGEM |  | scheduled | "Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm)) |
| August 6, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm)) |
| late 2026 | [Zipalertinib topline data readout](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | scheduled | "Taiho completed enrollment of the trial in February 2026 and expects to obtain top-line results by the end of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210304/cgem-20260331.htm)) |
| late 2026 | [Zipalertinib NDA/BLA submission](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | scheduled | "Completion of the Company's NDA submission is expected by year-end 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1789972/000119312526411011/cgem-20261001.htm)) |
| Q4 2026 | [Cullinan Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/cgem/catalysts) | CGEM | autoimmune diseases and initial clinical data | scheduled | "Genrix Bio is enrolling a Phase 1 study in China in patients with autoimmune diseases, initially in patients with SLE, followed by future planned expansion into other indications and initial clinical data from the study are expected to be shared in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/cgem-ex99_1.htm)) |
| Q4 2026 | [Cullinan Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | scheduled | "In Q4 2026, the Company plans to share initial data from the single target dose escalation portion of the study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm)) |
| Oct 2026 | [CLN-049 trial start](https://sec-api.dev/pdufa/cln-049) | CGEM | relapsed/refractory AML | completed | "In October 2026, we initiated a potentially registrational Phase 2 clinical trial in patients with relapsed/refractory AML." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1789972/000119312526454417/cgem-20260930.htm)) |
| Q4 2026 | [CLN-049 trial start](https://sec-api.dev/pdufa/cln-049) | CGEM | previously untreated AML | scheduled | "In Q4 2026, the Company will initiate a Phase 1/2 study evaluating the combination of CLN-049, venetoclax, and azacitidine in patients with previously untreated AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm)) |
| November 10, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526454408/cgem-ex99_1.htm)) |
| Q1 2027 | [CLN-978 trial start](https://sec-api.dev/pdufa/cln-978) | CGEM | autoimmune cytopenias | scheduled | "The Company plans to initiate a Phase 1/2a clinical trial in the first quarter of 2027 in patients with autoimmune cytopenias, including immune thrombocytopenia and autoimmune hemolytic anemia, autoantibody-mediated diseases with high unmet need." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/cgem-20260610.htm)) |
| February 27, 2027 | [Zipalertinib PDUFA date](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | scheduled | "An NDA for zipalertinib monotherapy for relapsed EGFR ex20ins NSCLC remains under review with a Prescription Drug User Fee Act target action date of February 27, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526454408/cgem-ex99_1.htm)) |

## Drugs

- [CLN-049](https://sec-api.dev/pdufa/cln-049): previously untreated aml, relapsed/refractory aml, newly diagnosed aml, aml and measurable residual disease
- [CLN-617](https://sec-api.dev/pdufa/cln-617): advanced solid tumors
- [CLN-619](https://sec-api.dev/pdufa/cln-619): relapsed/refractory multiple myeloma
- [CLN-978](https://sec-api.dev/pdufa/cln-978): moderate to severe sle, autoimmune cytopenias, rheumatoid arthritis, active, difficult-to-treat ra
- [Zipalertinib](https://sec-api.dev/pdufa/zipalertinib): active brain metastases

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cgem/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CGEM catalysts: Cullinan Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cgem/catalysts

```bibtex
@misc{secapidev_companies_cgem_catalysts_20261116,
  title        = {CGEM catalysts: Cullinan Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cgem/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cgem_catalysts_20261116","title":"CGEM catalysts: Cullinan Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cgem/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
